Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Neogen Delivers Strong Q1, Raises Fiscal 2027 Guidance Despite Selloff

Oct 7, 2026, 12:28 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Despite beating on EPS and revenue, NEOG's stock fell ~3% on the news, suggesting investors focused on order timing, modest top-line upside versus expectations, or broader macro concerns rather than the beat alone.

AI summary

What happened, with direct paths to the underlying reporting

Neogen reported a solid Q1 2027 with adjusted EPS of $0.08 on $222.8 million in sales, beating forecasts. The company lifted FY2027 revenue guidance to $885-890 million and EBITDA to $181-183 million, signaling continued profitable growth. Nonetheless, shares declined about 3% as investors weighed order timing and inflation-driven demand versus macro headwinds.

Q1 2027: NEOG beat on adjusted EPS and revenue.
Revenue $222.8m, +6.5% YoY; core revenue +8.1%.
Raised FY2027 revenue guidance to $885-890m; EBITDA $181-183m.
Stock fell ~3% despite positive quarter; orders timing weighed.
Food Safety growth led by Petrifilm; Animal Safety also strong.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Neogen Delivers Strong Q1, Raises Fiscal 2027 Guidance Despite Selloff

FDA Warning Raises Regulatory and Recall Risks for Neogen NEOG

NEOG Set for Q1 Earnings as Analyst Upgrades Lift Sentiment

Neogen Q3 Earnings Preview: Expectations Lower Amid Business Sale

Animal Health Firm Neogen Initiates Recall Of Vials Over Microbial Contamination